Dublin, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/zgwvjf/immunodiagnostics) has announced the addition of the "Immunodiagnostics Market in China 2016-2020" report to their offering.
This comprehensive report provides a detailed understanding of the various factors to affect the immunodiagnostics market in China over the coming years. The market is expected to stay healthy and to grow at an impressive CAGR of around 18% by 2020. The introduction of stringent healthcare reforms, growing preference for local manufacture of diagnostic devices, and rapidly increasing competition are some of the significant factors that augment growth in this market during the forecast period.
The immunodiagnostic market in the China is consolidated due to the presence of numerous small, medium, and large vendors. The vendors in this market compete on the basis of product differentiation, application differentiation, portfolio, and pricing to gain maximum market traction during the forecast period.
Questions Answered:
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the immunodiagnostic market in the China?
- What are the key Market trends impacting the growth of the immunodiagnostic market in the China?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the vendors in the immunodiagnostic market in the China?
- What are the key outcomes of the five forces analysis of the immunodiagnostic market in the China?
Companies Mentioned:
- Abbott Diagnostics
- Beckman Coulter Diagnostics
- Roche Diagnostics
- Siemens Healthcare Diagnostics
- BioSino Bio-technology & Science
- DiaSorin
- Immunodiagnostic System Holdings (IDS)
- Mindray Medical International
- Shanghai Kehua Bio-engineering
- Sichuan Maccura Biotechnology
Report Structure:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Healthcare system in China
PART 06: Market landscape
PART 07: Market segmentation by product type
PART 08: Market segmentation by analyzer type
PART 09: Market segmentation by mode of operation
PART 10: Market segmentation by technology
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
PART 17: Key vendor analysis
PART 18: Appendix
PART 19: About the Autho
For more information visit http://www.researchandmarkets.com/research/zgwvjf/immunodiagnostics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: In Vitro Diagnostics


Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Apple Turns 50: From Garage Startup to AI Crossroads
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 



